Shilpa Medicare Ltd
NSE:SHILPAMED

Watchlist Manager
Shilpa Medicare Ltd Logo
Shilpa Medicare Ltd
NSE:SHILPAMED
Watchlist
Price: 766.65 INR -1.48% Market Closed
Market Cap: 75B INR
Have any thoughts about
Shilpa Medicare Ltd?
Write Note

Shilpa Medicare Ltd
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Shilpa Medicare Ltd
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Shilpa Medicare Ltd
NSE:SHILPAMED
Income from Continuing Operations
â‚ą612.1m
CAGR 3-Years
19%
CAGR 5-Years
-9%
CAGR 10-Years
-3%
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Income from Continuing Operations
â‚ą54.3B
CAGR 3-Years
40%
CAGR 5-Years
20%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Income from Continuing Operations
â‚ą44.9B
CAGR 3-Years
20%
CAGR 5-Years
22%
CAGR 10-Years
14%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Income from Continuing Operations
â‚ą111.4B
CAGR 3-Years
21%
CAGR 5-Years
18%
CAGR 10-Years
5%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Income from Continuing Operations
â‚ą18B
CAGR 3-Years
12%
CAGR 5-Years
27%
CAGR 10-Years
8%
M
Mankind Pharma Ltd
NSE:MANKIND
Income from Continuing Operations
â‚ą19.4B
CAGR 3-Years
15%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Shilpa Medicare Ltd
Glance View

Market Cap
75B INR
Industry
Pharmaceuticals

Shilpa Medicare Ltd. engages in the manufacturing of pharmaceutical product and wind power generation. The company is headquartered in Raichur, Karnataka. The firm is engaged in manufacturing active pharmaceutical ingredients (APIs), formulation and development service. The company is focused on new drug delivery systems, peptides/biotech products and specialty chemicals. The Company’s product range include oncology and non-oncology APIs, oncology formulations, biosimilars, ophthalmic, oral dissolving films, biochemical diagnostics, organic intermediates, pilot and production scales and transdermal patches. The company supplies oncology/non-oncology APIs and intermediates. Its oncology APIs products include Capecitabine, Gemcitabine Hydrochloride, Axitinib, Erlotinib Hydrochloride and Irinotecan Hydrochloride for various regulated markets including USA, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets. Its non-oncology APIs products include Ambroxol (Mucolytic agent) in Europe and Tranexmic Acid and Ursodeoxycholic acid in India.

SHILPAMED Intrinsic Value
1 131.61 INR
Undervaluation 32%
Intrinsic Value
Price

See Also

What is Shilpa Medicare Ltd's Income from Continuing Operations?
Income from Continuing Operations
612.1m INR

Based on the financial report for Sep 30, 2024, Shilpa Medicare Ltd's Income from Continuing Operations amounts to 612.1m INR.

What is Shilpa Medicare Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
-3%

The average annual Income from Continuing Operations growth rates for Shilpa Medicare Ltd have been 19% over the past three years , -9% over the past five years , and -3% over the past ten years .

Back to Top